COMMUNIQUÉS West-GlobeNewswire

35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)
25/02/2026
Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary hypertension (PH) patients [...]
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
25/02/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]
Novonesis' Annual Report 2025
25/02/2026
Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester Baiget, President & CEO: ”In 2025, we [...]
Ethris Part of Consortium to Receive up to EUR 148 Million European Commission Contract to Advance Novel Pandemic Influenza Vaccine
25/02/2026
Initial tender contract of EUR 13 million supports gated advancement into two subsequent competitive phases MUNICH, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethris GmbH , a clinical-stage biotechnology company pioneering next- [...]
Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees
25/02/2026
Please read the full announcement in PDF Attachment 2026_02_LTI
Novonesis delivered strong organic sales growth of 7% in 2025
25/02/2026
COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester [...]
Ivim Health GLP-1 Weight Loss Program: Individualized Dosing, Pricing, and What Consumers Should Know in 2026
25/02/2026
An informational overview of Ivím Health's compounded semaglutide and tirzepatide telehealth program, including GLP-1 ID cost breakdown, weekly provider check-in structure, clinical claims analysis, and safety [...]
Pulmo Balance: Ingredients, Pricing, and What Consumers Should Know in 2026
25/02/2026
An informational overview examining category context, publicly available product disclosures, and what consumers often consider when researching respiratory support supplement options New York, NY, Feb. 24, 2026 (GLOBE [...]
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
25/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
25/02/2026
SHANGHAI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Globus Medical Reports Fourth Quarter and Full Year 2025 Results
24/02/2026
AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended [...]
Cannabix Technologies Closes Non-Brokered Private Placement
24/02/2026
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (the “Company” or “ [...]
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
24/02/2026
DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”) , a global leader in innovations for active healing, today announced that it will report financial results for [...]
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
24/02/2026
Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026 Improved balance sheet through multiple direct offerings; completed payments of [...]
Teva to Present at the Upcoming Investor Conferences in March
24/02/2026
PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the [...]
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
24/02/2026
Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating: • Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and [...]
Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors
24/02/2026
New directors bring decades of financial leadership and board experience to enhance strategic oversight of Return-to-Growth action plan and long-term value creation CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- [...]
Amwell® to Participate in Upcoming Investor Conference
24/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced that Mark Hirschhorn, CFO and COO, [...]
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
24/02/2026
LEXINGTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]

Pages